Nathan Connell: $50 Million Gift to Advance Cell and Gene Therapy at Mass General Brigham
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn:
“Transformational philanthropy is essential to advancing the next era of cellular and gene therapy.
The recently announced $50 million anonymous gift to support cancer research and cell and gene therapy across Mass General Brigham will help strengthen the infrastructure and translational science required to bring these therapies from discovery to patients.
In hematology, we are already beginning to see this shift in real time.
At Brigham and Women’s Hospital, our hemophilia program treated the first patient in New England with gene therapy for hemophilia B last year—a one-time infusion designed to enable the liver to produce factor IX, potentially replacing lifelong prophylactic factor therapy.
For patients who have spent decades managing a chronic bleeding disorder, the possibility that a single treatment could durably restore hemostasis represents a fundamental change in how we think about treatment.
Continued investment in academic gene therapy programs will be critical to expanding access, refining these approaches, and bringing the next generation of therapies to patients.
I am grateful to the visionary donors who are helping to accelerate our work.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies